會議于美國時間2019年6月13日下午1-6點在波士頓召開，屆時歡迎大家蒞臨參會。
 
Free to attend, light dinner will be provided. Join Biocytogen and AcroBiosystem to learn more about the cutting-edge technologies and latest research in biologic drug development. The symposium is co-organized by Biocytogen and AcroBiosystem, focusing mainly on therapeutic antibody and biologic drug discovery and development. 
 
Theme:Future of Biologic Drug Discovery and Development
Time:June 13th, 1:00 PM - 6:00 PM
Location:Residence Inn Boston Cambridge, 120  Broadway, Six Cambridge Center, Cambridge, MA

Confirmed Speakers
 
Chun-Nan Chen
CEO and CSO, Single Cell Technology
 
Qingcong Lin
CEO, Biocytogen Boston Corp
 
Stephen Gillies
CSO, LinkedUp Bioscience Inc

Johanna Lahdenranta
Director of In Vivo Pharmacology, Bicycle Therapeutics
 
Xiaodong Li
Associate of Patent and Intellectual Property, Choate, Hall & Stewart  LLP
 
Agenda

1:00 PM - 1:20 PM
Registration 

1:20 PM - 1:30 PM
Welcome Remark

1:30 PM - 2:00 PM
Introducing AbTheneum, A High Throughput and Data-rich Antibody Discovery Platform by Single Cell Technology
Chun-Nan Chen, CEO and CSO, Single Cell Technology
Named after an institution of great knowledge, AbTheneum™ is Single Cell Technology’s antibody discovery platform. Deploying AbTheneum™, we screen thousands of antibody-secreting cells for binding characteristics and sequence all the cells to return native heavy and light chain sequence pairs correlated with the binding activity for each antibody from single cells.  AbTheneum™ screening assay is flexible and can be customized for any target to find cross-reactivity, epitope specificity, and more.  Case studies will be shown for anti-BCMA and anti-FOLR1 antibody leads discovered using AbTheneum™ and their validation data. The discovery of these high-quality and therapeutically relevant antibody candidates highlights the power of AbTheneum™.

2:00 PM - 2:30 PM 
Accelerating Therapeutic Antibody Candidate Discovery using Biocytogen Humanized Mouse Models
Qingcong Lin, CEO, Biocytogen Boston Corp
The traditional therapeutic antibody discovery is a lengthy, multi-staged process from hit generation, lead screening, optimization to candidate selection. Depending on surrogate antibodies for efficacy tests in animal models has significantly constrained the therapeutic antibody discovery. This presentation will discuss three approaches to expedite the process. First, Biocytogen has generated thirty+ IO checkpoint humanized GEMM, enabling direct testing of anti-human antibodies in mice without depending on mouse cross-reactive antibody candidates. We have also created human CD3 knock-in mice for testing T cell-engaging bispecific antibodies. Second, our proprietary immunodeficient B-NDG and series of B-NDG variant mice are excellent host for engraftment of human PBMC and CD34+ hematopoietic stem cells and allow testing anti-human antibody candidate efficacy and safety. Finally, we have generated RenMab mice, by introducing the complete human heavy chain and light chain V(D)J regions to replace the mouse counterpart loci. A case study, where we considerably shortened the hit to lead process by conducting high-throughput in vivo efficacy-based lead identification using our humanized mice will also be presented.

2:30 PM - 3:00 PM
Humanized Mice for Studies of Immunocytokine Mono and Combi-therapies
Stephen Gillies, CSO, LinkedUp Bioscience Inc
3:00 PM - 3:30 PM
Coffee Break and Networking

3:30 PM - 4:00 PM
Activation of CD137 Using Multivalent and Tumor Targeted Bicyclic Peptides
Johanna Lahdenranta, Director of In Vivo Pharmacology, Bicycle Therapeutics

4:00 PM - 4:30 PM
Patent Portfolio Development for Biologic Products
Xiaodong Li,Associate of Patent and Intellectual Property, Choate, Hall & Stewart LLP
4:30 PM – 6:00 PM
Dinner Reception (Light dinner will be provided)

To register for the symposium, please go to "register"